Last reviewed · How we verify
Cefazolin for Injection
Cefazolin for Injection, marketed by the University of Michigan, is a well-established antibiotic with a key composition patent expiring in 2028. Its primary strength lies in its broad-spectrum activity and established efficacy, positioning it as a reliable option in the treatment of various bacterial infections. The primary risk is the potential increase in generic competition following the patent expiry in 2028, which could erode market share and revenue.
At a glance
| Generic name | Cefazolin for Injection |
|---|---|
| Sponsor | University of Michigan |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study (PHASE4)
- IO Vancomycin Spine (PHASE2, PHASE3)
- Antibiotics for Prevention of Infection Following Orthognathic Surgery (PHASE4)
- Comparison of a Morphomic-Based to the Standard-of-Care-Based Cefazolin Dose for Antimicrobial Prophylaxis (PHASE4)
- IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA (NA)
- A Multidisciplinary Perioperative Pain Management (NA)
- Pharmacokinetics Study of Cefazolin in Hemodialysis (CEFAZODIAL) (PHASE4)
- Antibioprophylaxis for Excision-graft Surgery in Burn Patient (A2B-TRIAL) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cefazolin for Injection CI brief — competitive landscape report
- Cefazolin for Injection updates RSS · CI watch RSS
- University of Michigan portfolio CI